All In Biotech

BLA 761067 · Sun Pharma Global

Ilumya

Tildrakizumab-Asmn · Injection · Interleukin-23 Antagonist

Novel

Last checked: Nov 20, 2026Latest source record: Oct 29, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2018

Mar 20, 2018

Approved uses

n/a

Original approval plus efficacy supplements

Registered trials

30

12 Phase 3, 5 recruiting

FAERS reports

0

0 serious, 0 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

No structured label for this application in openFDA. Older and discontinued products often have none.

Therapeutic areas: Immunology and inflammation

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

FDA's data service is rate-limiting requests. Try again in a minute. The numbers below may be missing or incomplete.

No approvals could be loaded from Drugs@FDA just now.

Clinical trials

Interventional ClinicalTrials.gov studies with "Tildrakizumab" as an intervention, any sponsor and status, largest first.

All 30 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
FDA's data service is rate-limiting requests. Try again in a minute. The numbers below may be missing or incomplete.

No FAERS reports name this application.

FAERS reports by year

By the date FDA received the report.

No reports.

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Ilumya (Tildrakizumab-Asmn)

2024 spending

$34.3M

Beneficiaries

696

2,020 claims

Per beneficiary

$49,213

$16,806.74 per unit

View as table
YearSpending
2020$13,660,369
2021$18,490,502
2022$25,027,537
2023$31,759,015
2024$34,252,143

Part B: Ilumya (Tildrakizumab-Asmn) · HCPCS J3245

2024 spending

$413M

Beneficiaries

9,049

30,861 claims

Per beneficiary

$45,684

2024 ASP limit $133.54 per unit

View as table
YearSpending
2020$66,825,098
2021$144,583,756
2022$251,905,420
2023$344,295,530
2024$413,395,382

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 86 on PubMed

Sponsor: Sun Pharma Global

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.